TY - JOUR
T1 - Pharmaceutical protein production by yeast: towards production of human blood proteins by microbial fermentation
AU - Martinez Ruiz, José Luis
AU - Liu, Lifang
AU - Petranovic, Dina
AU - Nielsen, Jens
PY - 2012
Y1 - 2012
N2 - Since the approval of recombinant insulin from Escherichia coli for its clinical use in the early 1980s, the amount of recombinant pharmaceutical proteins obtained by microbial fermentations has significantly increased. The recent advances in genomics together with high throughput analysis techniques (the so-called—omics approaches) and integrative approaches (systems biology) allow the development of novel microbial cell factories as valuable platforms for large scale production of therapeutic proteins. This review summarizes the main achievements and the current situation in the field of recombinant therapeutics using yeast Saccharomyces cerevisiae as a model platform, and discusses the future potential of this platform for production of blood proteins and substitutes.
AB - Since the approval of recombinant insulin from Escherichia coli for its clinical use in the early 1980s, the amount of recombinant pharmaceutical proteins obtained by microbial fermentations has significantly increased. The recent advances in genomics together with high throughput analysis techniques (the so-called—omics approaches) and integrative approaches (systems biology) allow the development of novel microbial cell factories as valuable platforms for large scale production of therapeutic proteins. This review summarizes the main achievements and the current situation in the field of recombinant therapeutics using yeast Saccharomyces cerevisiae as a model platform, and discusses the future potential of this platform for production of blood proteins and substitutes.
U2 - 10.1016/j.copbio.2012.03.011
DO - 10.1016/j.copbio.2012.03.011
M3 - Journal article
C2 - 22503236
SN - 0958-1669
VL - 23
SP - 965
EP - 971
JO - Current Opinion in Biotechnology
JF - Current Opinion in Biotechnology
IS - 6
ER -